We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trial.
- Authors
Shiroiwa, T.; Fukuda, T.; Shimozuma, K.; Mouri, M.; Hagiwara, Y.; Doihara, H.; Akabane, H.; Kashiwaba, M.; Watanabe, T.; Ohashi, Y.; Mukai, H.
- Abstract
<bold>Purpose: </bold>The goal of chemotherapy for metastatic breast cancer (MBC) is to prolong survival and maintain health-related quality of life. This study aimed to evaluate long-term health status of patients with MBC who participated in the phase III randomized SELECT BC trial.<bold>Methods: </bold>In the SELECT BC trial, patients were randomly allocated to the S-1 or taxane (paclitaxel or docetaxel) arm. Health status was assessed by EQ-5D at pre-treatment, 3 and 6 months after randomization, and every 6 months thereafter to the extent possible. Least square mean scores were assessed to compare EQ-5D index values between groups. Time to deterioration analysis was also performed by defining the minimally important difference of EQ-5D as 0.05 or 0.1.<bold>Results: </bold>The number of patients for EQ-5D analysis was 175 and 208 in the taxane and S-1 arms, respectively. Least square mean EQ-5D index values up to 60 months were 0.741 (95 % CI [0.713-0.769]) in the taxane arm and 0.748 [0.722-0.775] in the S-1 arm. The EQ-5D index value during PFS up to 12 months in the S-1 was superior to the corresponding index value in the taxane (0.812 [0.789-0.834] vs. 0.772 [0.751-0.792], P = 0.009). Time to deterioration analysis also revealed that S-1 significantly delayed the deterioration of EQ-5D index value during the period before progression (P = 0.002 and 0.003).<bold>Conclusions: </bold>Our findings suggest that the EQ-5D index value was higher in patients treated with S-1 during first-line chemotherapy. Considering non-inferiority of S-1 in terms of OS, obtained quality-adjusted life years may be greater in the S-1 arm.
- Subjects
BREAST cancer patients; HEALTH status indicators; QUALITY of life; METASTASIS; TAXANES; RANDOMIZED controlled trials; FLUOROURACIL; HYDROCARBONS; HETEROCYCLIC compounds; BREAST tumors; COMBINATION drug therapy; COMPARATIVE studies; RESEARCH methodology; MEDICAL cooperation; QUESTIONNAIRES; RESEARCH; EVALUATION research; QUALITY-adjusted life years; THERAPEUTICS; CANCER &; psychology
- Publication
Quality of Life Research, 2017, Vol 26, Issue 2, p445
- ISSN
0962-9343
- Publication type
journal article
- DOI
10.1007/s11136-016-1388-1